Heron Therapeutics Inc HRTX:NASDAQ

Last Price$18.75Cboe Real-Time Last Sale as of 2:28PM ET 6/03/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.29(1.57%)
Bid (Size)$18.74 (1)
Ask (Size)$18.75 (21)
Day Low / High$18.41 - 18.80
Volume377.2 K
  • Latest Stories
  • Commentary and Analysis
Analyst Actions: Guggenheim Starts Heron Therapeutics at Buy With $24 Price Target
9:28AM ET 5/27/2020 MT Newswires

Heron Therapeutics (HRTX) has an average analyst rating of buy, with an average price target of $42. Price: 19.05, Change: +0.61, Percent Change: +3.31 ...

Heron Therapeutics Commences Clinical Trial of Post-Operative Pain Medication
9:32AM ET 5/18/2020 MT Newswires

Heron Therapeutics (HRTX) said Monday that it has begun a phase 1b/2 clinical trial of HTX-034, the company's next-generation product for the treatment of...

Heron Therapeutics Q1 Loss Narrows, Revenue Declines
12:18PM ET 5/06/2020 MT Newswires

Heron Therapeutics (HRTX) on Wednesday posted a Q1 loss of $0.57, narrowing from $0.80 loss a year ago. Analysts polled by Capital IQ had expected a loss...

Heron Therapeutics Slips After Posting Worse-Than-Expected Q4 Loss Per Share; Revenue Tops Consensus
2:28PM ET 3/02/2020 MT Newswires

Heron Therapeutics (HRTX) on Monday posted a Q4 net loss of $0.65 per share, compared with a net loss of $0.63 per share a year earlier and wider than the...

Heron Therapeutics Down 4% After FDA Extends Review Period for HTX-011 Non-Opioid Pain Medication
1:57PM ET 2/20/2020 MT Newswires

Heron Therapeutics (HRTX) dropped 4% after the company said the US Food and Drug Administration extended the review period for the company's HTX-011 drug...

Analyst Actions: Needham & Co Cuts Heron Therapeutics Price Target to $48 From $50, Maintains Buy Rating
11:13AM ET 2/20/2020 MT Newswires

Heron Therapeutics' (HRTX) average rating among analysts is a buy, with an average price target of $47. Price: 20.21, Change: -1.45, Percent Change: -6.69...

Heron Therapeutics Says Drug for Postoperative Pain Receives Priority Review Status From Health Canada
9:11AM ET 12/03/2019 MT Newswires

Heron Therapeutics (HRTX) said Tuesday that Health Canada has accepted and granted a Priority Review Status for HTX-011, which is intended for the...

Heron Therapeutics Climbs After Q3 Results Beat Estimates, FDA Accepts Resubmission of Pain Treatment NDA
1:25PM ET 11/12/2019 MT Newswires

Heron Therapeutics (HRTX) was climbing by more than 3% Tuesday after the company booked a smaller Q3 GAAP loss of $0.42 per share than the $0.49 loss in...

Heron Therapeutics Receives FDA Acceptance for New Drug Application Resubmission for HTX-011
8:56AM ET 10/28/2019 MT Newswires

Heron Therapeutics (HRTX), a biotechnology company, reported that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)...

Heron Therapeutics' Cinvanti Receives Approval for Supplemental New Drug Application
10:14AM ET 10/22/2019 MT Newswires

Heron Therapeutics (HRTX) said Tuesday that it has received approval from the US Food and Drug Administration for its supplemental new drug application for...